

AVENUE STUDY

...for Active CNV Secondary to AMD



AVENUE STUDY

...for Active CNV Secondary to AMD

To investigate the safety, tolerability, pharmacokinetics and efficacy of RO6867461 administered intravitreally in patients with choroidal neovascularization secondary to AMD

*Principal Investigator
Dr. Matthew Ohr*

INCLUSION / EXCLUSION CRITERIA:

- At least 50 years of age
- Subfoveal CNV lesion of all types with a total lesion size of < 12 disc areas by FFA, CNV component area > 50% total lesion size, Active CNV confirmed by FFA, CNV exudation confirmed by spectral domain optical coherence topography
- Best corrected visual acuity in the study eye between 20/40 and 20/320
- Clear media and adequate pupillary dilation
- No CNV in either eye due to causes other than AMD
- No previous laser for CNV, DME RVO, or PDR
- No history of vitrectomy, glaucoma surgery, or any intraocular surgery
- No previous intravitreal corticosteroid injections
- Any anti-VEGF treatment for a retinal condition with 6 months prior to screening in fellow eye

CONTACT Havener Eye Institute Research Office • 614-293-5287 or • Research@osumc.edu

Will Bloom • Kim Rickard • 614-293-9161